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Abstract
Background—With changing patterns and increasing use of medical abortion in the United 
States, it is important to have accurate statistics on the use of this method regularly available. This 
study assesses the accuracy of medical abortion data reported annually to the Centers for Disease 
Control and Prevention (CDC) and describes trends over time in the use of medical abortion 
relative to other methods.
Study Design—This analysis included data reported to CDC for 2001–2008. Year-specific 
analyses included all states that monitored medical abortion for a given year, while trend analyses 
were restricted to states that monitored medical abortion continuously from 2001 to 2008. Data 
quality and completeness were assessed by (a) examining abortions reported with an unspecified 
method type within the gestational age limit for medical abortion (med-eligible abortions) and (b) 
comparing the percentage of all abortions and med-eligible abortions reported to CDC as medical 
abortions with estimates based on published mifepristone sales data for the United States from 
2001 to 2007.
Results—During 2001–2008, the percentage of med-eligible abortions reported to CDC with an 
unspecified method type remained low (1.0%–2.2%); CDC data and mifepristone sales estimates 
for 2001–2007 demonstrated strong agreement [all abortions: intraclass correlation coefficient 
(ICC)=0.983; med-eligible abortions: ICC=0.988]. During 2001–2008, the percentage of abortions 
reported to CDC as medical abortions increased (p<.001 for all abortions and for med-eligible 
abortions). Among states that reported medical abortions for 2008, 15% of all abortions and 23% 
of med-eligible abortions were reported as medical abortions.
Conclusion—CDC’s Abortion Surveillance System provides an important annual data source 
that accurately describes the use of medical abortion relative to other methods in the United States.
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In September 2000, the US Food and Drug Administration (FDA) approved the use of 
mifepristone in combination with misoprostol for medical abortion. Because medical 
abortion does not require specialized surgical skills or equipment and may be offered earlier 
in gestation than is typical for curettage procedures, it was anticipated that FDA approval 
would lead to the availability of abortion services through a wider range of providers and at 
earlier gestational ages [1,2]. During the initial years following FDA approval, use of 
mifepristone increased sharply, although subsequent increases were more gradual [3]. 
However, mifepristone use may be rising again [3], and in 2008, medical abortion accounted 
for more than 20% of US abortions performed up through the completion of 8 weeks’ 
gestation [4,5].
With changing patterns and increasing use of medical abortion, it is important to ensure that 
accurate statistics on the use of this method are regularly available. The Centers for Disease 
Control and Prevention (CDC) compiles abortion data reported by state health departments 
every year, including information on the methods used for abortion [4]. However, while 
most states legally require medical providers to submit a report for all the abortions they 
perform, there is no federal mandate. Thus, a few states do not have an abortion reporting 
system [6]. Moreover, because states establish their own reporting requirements, some states 
do not collect all the information CDC requests, and states also vary considerably in the 
degree to which reporting requirements are enforced [4,7]. Completeness of reporting may 
be especially problematic for capturing information on medical abortion. While the majority 
of medical abortions are provided at specialized abortion clinics with large caseloads [5], a 
higher percentage of the abortions provided in physician’s offices and small-caseload 
facilities are medical abortions [5,8]. Because it may be particularly difficult to identify 
providers who perform only a small number of abortions and identifying new providers in 
the wider medical community requires active surveillance efforts [8], medical abortions may 
be disproportionately undercounted even when reporting is technically required by law.
Through its periodic census of known abortion providers, the Guttmacher Institute provides 
an additional source of abortion data [5]. While this census generates the most complete 
national estimate of the total number of abortions performed in the United States [3,9], it is 
conducted only once every 3 or 4 years. Moreover, it does not obtain information on medical 
abortions from many of the providers surveyed and also may have difficulties identifying 
small-caseload providers [5,10]. Given these limitations, an additional source of data ideally 
should be used to evaluate the quality of CDC surveillance for medical abortion. Because 
the sole distributor of mifepristone in the United States only sells this medication to licensed 
physicians, who must sign and return a prescriber’s agreement [11], sales data from this 
company are not limited by the difficulties of identifying smaller providers within the wider 
medical community. Previously published estimates based on mifepristone sales data are 
available annually through 2007 [3].
Given the importance of having accurate estimates of the use of medical abortion in the 
United States regularly available, this study has the following objectives: (a) to assess the 
quality and completeness of CDC’s annual estimates of the use of medical abortion and (b) 
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to evaluate trends in the use of medical abortion relative to other methods, both among all 




Since 1969, CDC’s Abortion Surveillance System has documented the number and 
characteristics of women obtaining legal induced abortions in the United States. Each year, 
CDC requests states to provide aggregate abortion counts according to maternal 
demographics (age, race/ethnicity, residence, and previous live births and abortions), 
gestational age at the time of abortion, and the method used to complete the abortion. 
Additional details of CDC’s Abortion Surveillance System have been published elsewhere 
[4]. This analysis uses data from 2001 to 2008. Because this is public health surveillance 
data with no personal identifiers, this study was determined to be exempt from review by 
CDC’s Institutional Review Board.
2.2. Definitions
CDC compiles aggregate data on abortion methods by week of gestation using the following 
categories: curettage, medical, intrauterine instillation, other and unknown. CDC defines 
early medical abortion as the administration of medication or medications (typically 
mifepristone followed by misoprostol) to induce an abortion at ≤8 weeks’ gestation [4]. 
CDC collects information only on the estimated number of weeks (not days) of gestation 
and acknowledges the conventional use of completed weeks of gestation to describe 
pregnancy duration. CDC’s category “≤8 weeks’ gestation” thus includes abortions up 
through 8 weeks and 6 days, which closely corresponds to the gestational age limit of 63 
days for the early medical abortion protocol endorsed by the American College of 
Obstetricians and Gynecologists [12]. For this analysis, we defined an abortion that is 
eligible for medical abortion on the basis of gestational age (med-eligible abortion) as an 
abortion performed at ≤8 weeks’ gestation. Also for this analysis, we defined an abortion 
with an unspecified method type as an abortion reported to CDC as having been completed 
through an “other” or an “unknown” method.
2.3. Analysis
This analysis evaluated the reported use of early medical abortion from 2001 — the first full 
year following FDA approval of mifepristone — through 2008. Only states and other 
reporting areas (New York City and the District of Columbia) that specifically monitored the 
use of medical abortion were included (N=30–41, for a given year). Most reporting areas 
met this inclusion criterion by having medical abortion as a specific category on their 
reporting form. However, we retained Minnesota in our analyses for 2001–2006 despite the 
fact that it did not have medical abortion on its reporting form until 2007: whereas most 
states without medical abortion on their forms reported many abortions at ≤8 weeks’ 
gestation in the “other” or the “unknown” category, Minnesota supplied detailed notes in a 
text field that allowed >90% of these abortions to be reassigned to the medical abortion 
category. Measures of reported use included the percentage of all abortions that were 
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performed by early medical abortion and the percentage of med-eligible abortions that were 
performed by early medical abortion.
While states that did not have medical abortion on their reporting form tended to report a 
high percentage of abortions at ≤8 weeks’ gestation in the “other” or “unknown” categories, 
this pattern also was observed to varying degrees among states that did have medical 
abortion on their reporting form. Because this pattern suggests that even states with medical 
abortion on their reporting form may misclassify and therefore underascertain the use of 
early medical abortion, we used med-eligible abortions reported with an unspecified method 
type as an indicator of the quality and completeness of reporting for early medical abortion. 
For this analysis, we used two different measures: (a) abortions reported with an unspecified 
method type as a percentage of all med-eligible abortions and (b) the number of unspecified 
abortions relative to the number of early medical abortions. This second measure was used 
to control for greater opportunities for misclassification as the percentage of abortions 
performed medically increased.
To assess the quality and completeness of medical abortion reporting, we also compared 
CDC’s annual estimates of the percentage of abortions that were performed by early medical 
abortion with estimates based on published mifepristone sales data from 2001 to 2007 [3]. 
Because the estimates based on mifepristone sales data were published before the 
availability of estimates of the total number of abortions in the United States for 2006 and 
2007, for these years, the authors [3] calculated the percentage of abortions that were 
performed medically assuming that the downward trend in the total number of abortions 
from 2000 to 2005 [13] would continue through 2007. However, because data subsequently 
published for 2006 and 2007 indicated that the total number of abortions leveled off [5], we 
recalculated the contribution of mifepristone abortions for these years. For this calculation, 
we used the number of mifepristone abortions initially reported (numerator) [3] and the 
more recently published total number of abortions in the United States (denominator) [5]. 
Finally, to evaluate the robustness of CDC estimates relative to estimates based on 
mifepristone sales data, we considered alternative scenarios for each year from 2001 to 2007 
to assess the impact of reclassifying varying percentages of med-eligible abortions reported 
to CDC with an unspecified method type as early medical abortions. We hypothesized that 
med-eligible abortions reported with an unspecified method type were more likely to be 
medical than surgical abortions because of the tendency for some states to report abortions 
with an unspecified method type in a cluster at ≤8 weeks’ gestation.
Year-specific estimates of the percentage of abortions that were performed by early medical 
abortion included all reporting areas that monitored the use of medical abortion for a given 
year. Trend analyses only included areas that monitored the use of medical abortion every 
year during 2001–2008. We used the Spearman rank order correlation coefficient to evaluate 
changes across years in med-eligible abortions reported to CDC with an unspecified method 
type and the percentage of abortions that were performed by early medical abortion. We 
used the intraclass correlation coefficient (ICC) for absolute agreement with a two-way 
random-effects model to evaluate the agreement between CDC and mifepristone sales 
estimates of the percentage of abortions performed by early medical abortion. All statistical 
tests were completed in SPSS version 19 (IBM, Armonk, NY).
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For 2001, 30 reporting areas systematically collected and provided information to CDC on 
the use of medical abortion. From 2001 to 2008, the number of areas that reported medical 
abortion increased to 41, although only 28 states provided information on the use of medical 
abortion every year during this period.
Among the 28 continuously reporting areas, abortions reported with an unspecified method 
type constituted a very small percentage of all med-eligible abortions (1.0%–2.2%), and this 
percentage did not change during 2001–2008 (rs= −0.24; p=.57; Fig. 1). However, due to the 
increasing percentage of abortions that were performed medically (see below) the number of 
med-eligible abortions reported with an unspecified method type decreased relative to the 
number of early medical abortions (rs=−0.85; p<.01; Fig. 1).
Annual CDC estimates of the percentage of all abortions and med-eligible abortions that 
were performed medically differed by no more than one percentage point from the 
mifepristone sales estimates in any given year (Table 1). Thus, CDC and mifepristone sales 
estimates of early medical abortion demonstrated strong absolute agreement (all abortions: 
ICC= 0.983; med-eligible abortions: ICC=0.988). The degree of agreement between the two 
estimates for all abortions and for med-eligible abortions was greatest when we assumed that 
40% of med-eligible abortions reported to CDC with an unspecified method type actually 
were early medical abortions (all abortions: ICC=1.00; med-eligible abortions: ICC= 0.995). 
Assuming that >40% of med-eligible abortions reported to CDC with an unspecified method 
type actually were medical abortions did not result in greater agreement (Table 1).
Among the 41 areas that reported medical abortion data to CDC for 2008, 15% of all 
abortions and 23% of med-eligible abortions were reported as early medical abortions. After 
applying the assumption that 40% of med-eligible abortions reported to CDC with an 
unspecified method type were medical abortions, the estimate for all abortions remained at 
15% and the estimate for med-eligible abortions increased only one percentage point, to 
24%.
Among the 28 continuously reporting areas that provided CDC data on medical abortion 
every year during 2001–2008, the percentage of all abortions and med-eligible abortions that 
were performed by early medical abortion increased over time (all abortions: rs=0.99, p<.
001; med-eligible abortions: rs=1.00, p<.001; Fig. 2). Annual estimates among the 
continuously reporting areas changed by no more than one percentage point if it was 
assumed that a certain percentage (10%–60%) of med-eligible abortions reported to CDC 
with an unspecified method type were early medical abortions.
During 2001–2003, the percentage of all abortion and med-eligible abortions that were 
performed by early medical abortion increased. In 2004 and 2005, the contribution of 
medical abortion leveled off but began increasing again in 2006 (Fig. 2).
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This analysis points to the strength of CDC’s Abortion Surveillance System for monitoring 
the percentage of abortions that are performed medically in the United States. Annual early 
medical abortion estimates based on surveillance data reported to CDC were essentially 
identical to national estimates based on mifepristone sales data. Moreover, the quality and 
completeness of CDC’s annual estimates have improved over time: the number of areas 
reporting the use of medical abortion to CDC increased from 30 in 2001 to 41 in 2008. 
Additionally, abortions reported with an unspecified method type accounted for a very small 
percentage of all med-eligible abortions, and the number of med-eligible abortions reported 
with an unspecified method type decreased relative to the number of early medical abortions 
over the study period.
This study also suggests that the percentage of abortions completed by early medical 
abortion has begun to increase more rapidly in recent years. The current analysis shows that 
the use of early medical abortion increased quickly in the initial years following FDA 
approval of mifepristone and then plateaued during 2004–2006; however, during 2007–
2008, more pronounced increases were observed once more. Hence, while early medical 
abortion currently accounts for 23% of med-eligible abortions, further increases are possible. 
Full integration of early medical abortion into US abortion practices could resemble the 
pattern observed in many European countries, where increases in the use of mifepristone 
took place over many years as health care systems adapted to new regulations and protocols 
[14]. Because CDC data are available annually, they represent an important source of 
information for monitoring trends and determining whether a similar pattern might occur in 
the United States.
Another strength of CDC’s abortion surveillance data is that information on use of different 
abortion methods can be reported by gestational age. Given the potential advantages of 
using mifepristone as an adjuvant in abortion by labor induction and in dilation and 
evacuation procedures [15–17], it may increasingly be used in second-trimester abortions. If 
so, mifepristone sales data will overestimate the use of early medical abortion. By 
combining information on gestational age and abortion method, CDC data can be used to 
identify abortions for which mifepristone was used for purposes other than early medical 
abortion, thereby more accurately estimating the percentage of early abortions that are 
performed by early medical abortion.
One reason for the close correspondence of estimates based on data reported to CDC and 
mifepristone sales data may be that early medical abortion is not being offered by as wide of 
a range of providers as was anticipated initially. Although identifying small-caseload 
providers in the wider medical community is challenging [8], existing data suggest that the 
number of abortions provided in physician’s offices and small-caseload facilities decreased 
from 2005 to 2008 [5] and that early medical abortion continues to be offered primarily by 
obstetrician-gynecologists [3]. Several factors may limit the number and range of providers 
who offer early medical abortion. First, many states recently have passed laws requiring 
facilities that offer abortion services to meet the building standards of an ambulatory 
surgical center [18,19]. Because these regulations may apply to facilities offering medical as 
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well as surgical abortions, it may be financially impossible for private offices and small-
caseload providers to offer any type of abortion services. Similarly, the cost and availability 
of liability insurance may prevent many family physicians from offering medical abortion: 
they may be refused coverage for abortion, or they may be charged the same liability 
insurance premiums for providing medical abortions as for providing surgical abortion 
procedures [20]. Finally, it was anticipated that the use of telemedicine (i.e., the delivery of 
health care services at a distance using information and communication technology) and the 
provision of early medical abortion by advanced practice clinicians (i.e., physician 
assistants, nurse practitioners and certified nurse-midwives) would increase the availability 
of abortion services in remote areas with relatively few physicians and surgical facilities 
[21,22]. However, most states have laws preventing advanced practice clinicians from 
providing abortion services, and these laws have been applied to medical as well as surgical 
abortions [23]. Additionally, a number of states have begun to pass laws prohibiting 
physicians from using telemedicine to provide medical abortions remotely [18].
This analysis is not without limitations. First, although mifepristone sales data were used as 
a comparison for CDC data, mifepristone also may be used for second-trimester procedures 
[15–17]. Mifepristone sales data, therefore, may overestimate the use of early medical 
abortion. Conversely, methotrexate offers another option for early medical abortion [24] that 
would have been included in the CDC estimates, but not the estimates based on mifepristone 
sales data. Similarly, misoprostol alone, although not as effective as the combination of 
mifepristone and misoprostol and not recommended where mifepristone is available, can be 
used for early medical abortion [24,25]. Nonetheless, in spite of these alternatives, prior to 
FDA approval of mifepristone, the percentage of abortions reported to CDC as medical 
abortions remained very low (≤1%) [26]. Finally, use of estimates based on mifepristone 
sales data as a comparison for CDC data assumes that providers are using mifepristone units 
in the year of purchase and that providers comply with the evidence-based (200-mg 
mifepristone dose) medical abortion protocol. Although these assumptions appear valid 
[3,27], given the increasing number of states requiring providers to comply with the current 
FDA-approved protocol (600-mg mifepristone dose) [18], a certain percentage of early 
medical abortions will be performed with this higher dose of mifepristone until a relabeling 
of this product is approved.
Another limitation is that the gestational age cutoff of ≤8 weeks misclassifies a small 
proportion of early medical abortions performed at 63 days’ gestation. The dramatic 
decrease in medical abortion after 8 weeks’ gestation that has been documented in CDC data 
[4] suggests that this gestational age cutoff is appropriate for the purpose of surveillance. 
However, given research showing continuing efficacy of mifepristone and misoprostol 
between 9 and 13 weeks’ gestation [28–33], this cutoff will need to be reconsidered upon 
any indication of changes in abortion practice patterns in the United States. CDC will 
continue to monitor patterns in reported use of medical abortion by gestational age and 
adjust its classification of abortions as necessary.
In conclusion, this analysis suggests that CDC’s Abortion Surveillance System provides a 
valuable measure of the use of early medical abortion relative to other methods for abortion 
in the United States. Importantly, CDC data are available annually and can capture rapid 
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changes in usage patterns. Even during the initial years following FDA approval of 
mifepristone, CDC estimates of the percentage of abortions that were performed medically 
closely matched estimates from other sources, and the quality and completeness of CDC 
surveillance data appear to have improved over time. The most recent CDC data suggest that 
the percentage of abortions that are performed medically is rising. Because CDC abortion 
surveillance data are available annually, they are an important source of information for 
determining whether the recent increase is part of a sustained trend.
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Abortions reported with an unspecified method type among med-eligible abortions in 28 
continuously reporting areas, 2001–2008.
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Percentage of abortions that were early medical abortions among 28 continuously reporting 
areas, 2001–2008.
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